Eisai Mediaroom

RECENT RELEASES

Jun 1, 2020

Eisai Announces U.S. Availability of DAYVIGO™ (lemborexant) CIV, a New Treatment Option for Adults With Insomnia

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...